Antibody-induced procoagulant platelets in severe COVID-19 infection.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
25 02 2021
Historique:
received: 20 08 2020
accepted: 09 12 2020
pubmed: 30 1 2021
medline: 9 3 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

The pathophysiology of COVID-19-associated thrombosis seems to be multifactorial. We hypothesized that COVID-19 is accompanied by procoagulant platelets with subsequent alteration of the coagulation system. We investigated depolarization of mitochondrial inner transmembrane potential (ΔΨm), cytosolic calcium (Ca2+) concentration, and phosphatidylserine (PS) externalization. Platelets from COVID-19 patients in the intensive care unit (ICU; n = 21) showed higher ΔΨm depolarization, cytosolic Ca2+, and PS externalization compared with healthy controls (n = 18) and non-ICU COVID-19 patients (n = 4). Moreover, significant higher cytosolic Ca2+ and PS were observed compared with a septic ICU control group (ICU control; n = 5). In the ICU control group, cytosolic Ca2+ and PS externalization were comparable with healthy controls, with an increase in ΔΨm depolarization. Sera from COVID-19 patients in the ICU induced a significant increase in apoptosis markers (ΔΨm depolarization, cytosolic Ca2+, and PS externalization) compared with healthy volunteers and septic ICU controls. Interestingly, immunoglobulin G fractions from COVID-19 patients induced an Fcγ receptor IIA-dependent platelet apoptosis (ΔΨm depolarization, cytosolic Ca2+, and PS externalization). Enhanced PS externalization in platelets from COVID-19 patients in the ICU was associated with increased sequential organ failure assessment score (r = 0.5635) and D-dimer (r = 0.4473). Most importantly, patients with thrombosis had significantly higher PS externalization compared with those without. The strong correlations between markers for apoptosic and procoagulant platelets and D-dimer levels, as well as the incidence of thrombosis, may indicate that antibody-mediated procoagulant platelets potentially contributes to sustained increased thromboembolic risk in ICU COVID-19 patients.

Identifiants

pubmed: 33512415
pii: S0006-4971(20)86032-7
doi: 10.1182/blood.2020008762
pmc: PMC7791311
doi:

Substances chimiques

Immunoglobulin G 0
Phosphatidylserines 0
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1061-1071

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 by The American Society of Hematology.

Références

Blood. 2014 May 1;123(18):2854-63
pubmed: 24665136
Mediators Inflamm. 2015;2015:313842
pubmed: 25999666
J Thromb Haemost. 2020 Jun;18(6):1469-1472
pubmed: 32302435
J Thromb Haemost. 2020 Sep;18(9):2103-2109
pubmed: 32558075
Res Pract Thromb Haemost. 2018 May 20;2(3):450-460
pubmed: 30046749
Pathol Res Pract. 2010 Mar 15;206(3):145-50
pubmed: 20097014
Blood. 2020 Sep 10;136(11):1317-1329
pubmed: 32573711
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Blood. 2008 Feb 1;111(3):1257-65
pubmed: 17989312
J Infect Dis. 2012 Apr 15;205(8):1321-9
pubmed: 22383677
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
Front Immunol. 2019 Sep 13;10:2204
pubmed: 31572400
Sci Rep. 2018 Oct 9;8(1):14999
pubmed: 30301959
Haematologica. 2019 Dec 19;106(1):196-207
pubmed: 31857361
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Hamostaseologie. 2018 Nov;38(4):186-202
pubmed: 30253422
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
J Thromb Haemost. 2013 Jan;11(1):2-16
pubmed: 23106920
Br J Haematol. 2014 Apr;165(2):217-26
pubmed: 24467740
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Sci Rep. 2020 Feb 3;10(1):1728
pubmed: 32015442
Blood Adv. 2019 Dec 10;3(23):4021-4033
pubmed: 31809536
Nat Rev Cardiol. 2019 Mar;16(3):166-179
pubmed: 30429532
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
DNA Cell Biol. 2005 Aug;24(8):496-502
pubmed: 16101347
J Thromb Haemost. 2013 May;11(5):951-62
pubmed: 23433144
Thromb Haemost. 2020 Jun;120(6):949-956
pubmed: 32349133
Atherosclerosis. 2018 Nov;278:269-277
pubmed: 30342381
Cell. 2007 Mar 23;128(6):1173-86
pubmed: 17382885
Cell Death Differ. 2007 May;14(5):943-51
pubmed: 17205078
Lancet Haematol. 2020 Jun;7(6):e438-e440
pubmed: 32407672
Blood. 2010 Sep 23;116(12):2011-8
pubmed: 20538794
JCI Insight. 2018 May 17;3(10):
pubmed: 29769447
Front Med (Lausanne). 2018 Apr 30;5:121
pubmed: 29761104
Blood. 2018 Feb 8;131(6):605-610
pubmed: 29259001
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10682-E10691
pubmed: 30337485
Front Immunol. 2019 Jul 17;10:1687
pubmed: 31379873
Circ Res. 2014 Nov 7;115(11):939-49
pubmed: 25266363
Platelets. 2020 Aug 17;31(6):740-745
pubmed: 32456506
Thromb Res. 2017 Jul;155:106-115
pubmed: 28528289
Blood Adv. 2020 Jan 14;4(1):154-164
pubmed: 31935287
J Thromb Haemost. 2020 Nov;18(11):3067-3073
pubmed: 32945081
Thromb Res. 2008;122(4):473-7
pubmed: 18314161

Auteurs

Karina Althaus (K)

Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen.
Centre for Clinical Transfusion Medicine, and.

Irene Marini (I)

Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen.

Jan Zlamal (J)

Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen.

Lisann Pelzl (L)

Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen.

Anurag Singh (A)

Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen.

Helene Häberle (H)

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Tuebingen, Tuebingen, Germany.

Martin Mehrländer (M)

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Tuebingen, Tuebingen, Germany.

Stefanie Hammer (S)

Centre for Clinical Transfusion Medicine, and.

Harald Schulze (H)

Institute for Experimental Biomedicine, University Hospital Wuerzburg, Wuerzburg, Germany; and.

Michael Bitzer (M)

Department of Internal Medicine I.

Nisar Malek (N)

Department of Internal Medicine I.

Dominik Rath (D)

Department of Internal Medicine III, and.

Hans Bösmüller (H)

Institute for Pathology, University Hospital of Tuebingen, Tuebingen, Germany.

Bernard Nieswandt (B)

Institute for Experimental Biomedicine, University Hospital Wuerzburg, Wuerzburg, Germany; and.

Meinrad Gawaz (M)

Department of Internal Medicine III, and.

Tamam Bakchoul (T)

Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen.
Centre for Clinical Transfusion Medicine, and.

Peter Rosenberger (P)

Department of Anesthesiology and Intensive Care Medicine, University Hospital of Tuebingen, Tuebingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH